Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or RefractoryCD22-expressing B Cell Malignancies

Trial Profile

Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or RefractoryCD22-expressing B Cell Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Oct 2017

At a glance

  • Drugs JCAR 018 (Primary)
  • Indications Acute lymphoblastic leukaemia; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Jun 2017 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.
    • 09 Jun 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
    • 06 Jun 2017 Planned number of patients changed from 67 to 115.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top